Clinical Trial Details
— Status: Not yet recruiting
Administrative data
| NCT number |
NCT06108570 |
| Other study ID # |
TOPIAbis-2022 |
| Secondary ID |
B4032023000074 |
| Status |
Not yet recruiting |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
November 2023 |
| Est. completion date |
May 2024 |
Study information
| Verified date |
October 2023 |
| Source |
SVR Group |
| Contact |
Natacha COLLARD PEIGNÉ |
| Phone |
0033 0188400313 |
| Email |
natacha.collard[@]labo-svr.com |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
The purpose of this study is to evaluate the efficacy and tolerability of a SVR care product.
As we know, atopic dermatitis is a vicious circle that must be broken, but certain
aggravating factors are added to this circle. There is a lot of talk about pollution but,
more recently, studies have been carried out on the worsening role of dust mites on atopic
skin.
TOPIALYSE Baume Protect+ is a care product that is lipid-replenishing, repairing and
protective: a triple reinforced action for 48 hours: anti-scratching, anti-irritation, and
external anti-aggression. It is also intended for the whole family from birth for dry skin
with an atopic tendency (with atopic eczema).
The main objective of this study is to evaluate the efficacy of the cosmetic product SVR
TOPIALYSE Baume Protect+ versus Neutral Product on patients with mild atopic dermatitis,
after 4 weeks of use with evaluation of the evolution mEASI (modified Eczema Area and
Severity Index)
Description:
1. RATIONALE : The purpose of this study is to evaluate the efficacy and tolerability of a
SVR care product.
As we know, atopic dermatitis is a vicious circle that must be broken, but certain
aggravating factors are added to this circle. There is a lot of talk about pollution but,
more recently, studies have been carried out on the worsening role of dust mites on atopic
skin.
The new SVR product, TOPIALYSE Baume Protect+ will therefore be based on it.
TOPIALYSE Baume Protect+ is a care product that is lipid-replenishing, repairing and
protective: a triple reinforced action for 48 hours: anti-scratching, anti-irritation, and
external anti-aggression. It is also intended for the whole family from birth for dry skin
with an atopic tendency (with atopic eczema).
2 STUDY OBJECTIVES 2.1 PRIMARY OBJECTIVE: The main objective of this study is to evaluate the
efficacy of the cosmetic product SVR TOPIALYSE Baume Protect+ versus Neutral Product on
patients with mild atopic dermatitis, after 4 weeks of use with evaluation of the evolution
mEASI (modified Eczema Area and Severity index ).
2.2 SECONDARY OBJECTIVE:
- To assess the tolerance of TOPIALYSE Baume Protect+ versus Neutral Product by a scale of 0
to 5, (0 corresponding to no reaction and 5 to severe) after 4 weeks of application.
- To assess the product's efficacy in improving children's quality of life using the IDQOL
questionnaire (Infant's Dermatitis Quality of Life index ).
- To assess the efficacy of the product on the reduction of pruritus using the Visual
Analog Scale (VAS).
- Taking of close-up photographs of the lesions / anonymized when the patients or their
parent(s) have given their consent.
- Analysis of the subjects' answers to a subjective product evaluation questionnaire.
3.STUDY METHODOLOGY This is a multicentric, randomized, intra-individual and
double-blind study. It is an interventional study with minimal risks (Category 2).
3.1 EVALUATION CRITERIA 3.1.1 Primary criteria • Evaluation of the efficacy of the product by
reducing the symptoms associated with mild atopic dermatitis with evaluation of the evolution
of the mEASI (modified Eczema Area and Severity index).
3.1.2 Secondary criteria
- Assessment of the tolerance of TOPIALYSE Baume Protect+ versus Neutral Product on a
scale of 0 to 5, (0 corresponding to no reaction and 5 to severe) after 4 weeks of
application.
- Assessment of the product's efficacy in improving children's quality of life using the
IDQOL questionnaire (Infant's Dermatitis Quality of Life index).
- Evaluation of the efficacy of the product on the reduction of pruritus using the Visual
Analog Scale (VAS).
- Taking of close-up photographs of the lesions / anonymized when the patients or their
parent(s) have given their consent.
- Analysis of the subjects' answers to a subjective product evaluation questionnaire.
- General safety: General Adverse Events will be reported descriptively on an on-going
basis.
3.2 EVALUATION METHODS
3.2.1 Modified Eczema Area and Severity Index At D0 and D28±3, the dermatologist calculates
the mEASI over the entire body. A. First, the investigator selects the affected areas. B. For
each zone, the investigator assesses the severity of the 4 signs of atopic dermatitis
(erythema, oedema/papulation, excoriation, lichenification) from 0 to 3 on the selected area.
C. For each zone, the investigator assesses the extent of atopic dermatitis in that area.
D. Then the investigator will obtain the mEASI score of each area after applying the
multiplying factor. The multiplying factor may be different if the patient is less than 8
years old.
3.2.2 IDQOL At D0 and D28±3, the dermatologist calculates the SCORE IDQOL using the
Quality-of-Life Questionnaire on Early Childhood Eczema completed by the parents.
To obtain the IDQOL score, the investigator adds up the scores given for each response with a
maximum of 30 and a minimum of 0. The higher the score, the greater the impact on quality of
life. The severity of eczema is scored separately and can be correlated with the IDQOL score.
3.2.3 Pruritus assessment Pruritus will be assessed using the visual analogue scale VAS at
Day 0 before product application and at Day 28±3.
3.2.4 Subjective evaluation questionnaire A subjective evaluation questionnaire is completed
by subjects at D28±3 to subjectively assess the efficacy and acceptability of the product
studied.
3.2.5 Standardized photographs Standardized photographs of the affected areas (body and/or
face) if authorized and desired will be performed at D0 and D28±3
4.Duration of treatment The tested products will be applied for twenty-eight to thirty-one
days consecutively.
5.Dose For the test products an amount of about 2mg/cm² on a whole child body test area
(0,46m² (1-year-old babies) to 1,85m² (adolescents) area [25]) will be applied once a day or
twice a day. The subject will be shown the amount of product to be applied.
6 INVESTIGATIONAL PLAN 6.1 STUDY DESIGN This is a multicentric, randomized, intra-individual
and double-blind study. It is an interventional study with minimal risks (Category 2).
The study will be performed in sixty children with mild atopic dermatitis, seventy-two (72)
will be pre-screened if we consider a risk of approximately 20% drop-out. The screening of
the subjects will be performed at the investigator's medical office within three months prior
to the first study visit (at Day 0) and to allow verification of the subject compatibility
with the inclusion and exclusion criteria. During the screening visit a physical examination
and vital sign measurement will be performed.
6.1.1 Study location The study will be performed in five Investigation centers.
6.1.2 Study duration The study participation for each subject will last up to 1 month (28±3
days of clinical participation).
6.2 STUDY PROCEDURES 6.2.1 Screening visit: The screening visit will be performed within
three months of the day before Day 0. The following procedures may be carried on several days
if needed.
- Subject information and presentation of the informed consent form,
- Inclusion/ exclusion criteria checking.
6.2.2 Visit 1 Baseline: Day 0
The subject will have to come to the investigator site for:
- Signing the consent form
- Verification of inclusion and non-inclusion criteria
- Clinical examination / Medical history
- Randomization
- Complete source file and CRF
- mEASI clinical scoring
- IDQOL questionnaire
- Assessment of pruritus with the VAS
- Taking of standardized photographs if applicable
- Distribution of products in relation to randomization
- Weigh study products and record in the source file and CRF
- Distribution of logbook and patient card
- First application of products in office (left/right)
- Schedule next appointment for D28-D31.
Between this visit and the next:
- Use of the products
- Daily filling of the logbook.
6.2.3 Visit 2, Follow-up and the end of the study: Day 28±3
- Verification of the patient logbook
- Follow-up of adverse events, intolerance and associated treatments
- Fill in the source file and the CRF
- mEASI clinical scoring
- IDQOL questionnaire
- Evaluation of pruritus with the VAS scale
- Taking of standardized photographs if applicable
- Subjective evaluation questionnaire
- Collection of follow-up booklets
- Collection of study products
- Weigh the products and record in the source file and CRF
- End of study. After this visit, the patients will stop using the TOPIALYSE Baume
Protect+ emollient and the neutral product.
8 STATISTICAL METHODS 8.1 BASELINE CHARACTERISTICS Continuous demographic variables
(e.g. age, weight, and height) will be summarized, using mean, standard deviation,
minimum, maximum and number of available observations.
Qualitative demographic characteristics will be summarized by counts and percent. Other
subject characteristics (anomalies in physical examination, prior medication, inclusion /
exclusion checklist) will be listed only.
8.2 PRIMARY CRITERION
• Evaluation of the efficacy of the product by reducing the symptoms associated with mild
atopic dermatitis with evaluation of the evolution of the mEASI (modified Eczema Area and
Severity Index)
8.3 SECONDARY CRITERIA
- Evaluation of the tolerance of TOPIALYSE Baume Protect+ versus Neutral Product by a
scale of 0 to 5, (0 corresponding to no reaction and 5 to severe) after 4 weeks of
application.
- Evaluation of the product's efficacy in improving children's quality of life using the
IDQOL questionnaire (Infant's Dermatitis Quality Of Life index).
- Evaluation of the efficacy of the product on the reduction of pruritus using the Visual
Analog Scale (VAS).
- Taking of close-up photographs of the lesions / anonymized when the patients or their
parent(s) have given their consent.
- Analysis of the subjects' answers to a subjective product evaluation?questionnaire.
- General safety: General Adverse Events will be reported descriptively on an on-going
basis.
8.4 STATISTICAL ANALYSES Descriptive statistics (N, mean, standard error, min, max,) will be
calculated by test product for each parameter.
Prior to any statistical analysis, the normality of each variable will be tested using the
Shapiro Wilks test of normality.
Statistical Tests For each normal variable, comparisons will be performed using a t-test for
paired data.
For each non normal variable, comparison will be performed using a Wilcoxon rank sum test.
8.5 NUMBER OF SUBJECTS CALCULATION The expected benefit is an improvement in the severity of
atopic dermatitis with a decrease in EASI / mEASI.
A literature review shows that for a mean baseline EASI of 4.49, patients with mild to
moderate atopic dermatitis treated with a class 1 topical medical device enriched with
antioxidants twice daily for 28 days [26] showed a decrease of this score of 3.41 (standard
deviation of the baseline population = 3.87). We expect similar results given the
compositions of the medical device and the tested product, as well as a slighter effect with
the placebo (decrease of about 0.5 with the placebo). These different parameters define a
Cohen effect size of d=0.75, i.e., a strong effect. A calculation of the number of subjects
shows that with an α level of 0.05 (one-sided) and a power of 80%, we obtain a total number
of subjects of 46. A minimum of 23 patients per group would therefore be needed according to
this scheme.
